141 results on '"MacLeod, A. Robert"'
Search Results
2. A Systematic Online Living Evidence Summary of experimental Alzheimer’s disease research
3. Abstract 1196: The epigenetic impact and therapeutic opportunity of AR-directed therapy for DSRCT
4. Supplementary Figure 1 from Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo
5. Supplementary Figure 1 from Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo
6. Data from Transcription Factor Stat5 Knockdown Enhances Androgen Receptor Degradation and Delays Castration-Resistant Prostate Cancer Progression In vivo
7. Supplementary Table 1 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
8. Supplemental Figure Legends and Mathods from Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
9. Data from Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer
10. Supplemental Figure Legends and Mathods from Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
11. Data from Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer
12. Data from An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1−HK2+ Multiple Myeloma
13. Supplemental Figures from An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1−HK2+ Multiple Myeloma
14. Supplementary Table 2 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
15. Data from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
16. Supplementary Figures from Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer
17. Data from An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1−HK2+ Multiple Myeloma
18. Supplemental Table S1 from An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1−HK2+ Multiple Myeloma
19. Supplemental Table S1 from An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1−HK2+ Multiple Myeloma
20. Supplemental Figures from An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1−HK2+ Multiple Myeloma
21. Supplementary Table 2 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
22. Supplemental Materials and Methods from An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1−HK2+ Multiple Myeloma
23. Supplementary Table 1 from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
24. Supplemental Materials and Methods from An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1−HK2+ Multiple Myeloma
25. Supplemental Figure 1 from Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth
26. Data from MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
27. Supplementary Methods, Figures 1 - 4, Tables 2 - 6 from The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
28. Supplementary Table 1 from The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
29. Data from The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
30. Supplementary Table 1 from The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
31. Supplementary Methods, Figures 1 - 4, Tables 2 - 6 from The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
32. Data from The Noncoding RNA MALAT1 Is a Critical Regulator of the Metastasis Phenotype of Lung Cancer Cells
33. EFFECTS OF GALACTO-OLIGOSACCHARIDE PREBIOTICS IN THE FLINDERS SENSITIVE LINE RAT MODEL OF DEPRESSION ON BEHAVIOURAL OUTCOMES
34. Screening for in vitro systematic reviews: a comparison of screening methods and training of a machine learning classifier
35. Systematic Online Living Evidence Summaries: emerging tools to accelerate evidence synthesis
36. Open Research, Research Culture and Research Integrity
37. The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma
38. Corrigendum to: ‘Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target’ [J Hepatol 2021 (74) 1155-1166]
39. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer
40. Inhibition of Prekallikrein for Hereditary Angioedema
41. Targeting Long Noncoding RNA with Antisense Oligonucleotide Technology as Cancer Therapeutics
42. The Androgen Receptor: A Therapeutic Target in Desmoplastic Small Round Cell Sarcoma
43. Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity
44. Antisense oligonucleotide activity in tumour cells is influenced by intracellular LBPA distribution and extracellular vesicle recycling
45. Plasma Kallikrein Contributes to Intracerebral Hemorrhage and Hypertension in Stroke-Prone Spontaneously Hypertensive Rats
46. Abstract ND11: The discovery and characterization of ION-537: A next generation antisense oligonucleotide inhibitor of YAP1 in preclinical cancer models
47. Sensitive intranuclear flow cytometric quantification of IRF4 protein in multiple myeloma and normal human hematopoietic cells
48. Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target
49. Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption
50. Correction to: LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.